InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,289.24
(
0.07%
)
Post# of 647879
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

BioSpecialist

Send PM Follow Ignore
Followers 129
Posts 2150
Boards Moderated 1
Alias Born 12/27/2007

BioSpecialist

Re: AugustaFriends post# 431414

Monday, 01/06/2020 6:21:43 PM

Monday, January 06, 2020 6:21:43 PM

Post# of 647879
TNXP ..Phase 3 interim results of the posttraumatic stress disorder (PTSD) trial expected during this Quarter .Extremely low valuation of only $13 million this could run towards $10 and higher especially on positive phase 3 outcome .


from Zacks article :

We are looking forward to the results of the interim analysis for the RECOVERY trial in the first quarter of 2020, and pending the outcome of that analysis, topline results in the second quarter of 2020. Based on the results of 2.8 mg TNX-102 SL in the AFFIRM trial, we believe there is a high likelihood of success for 5.6 mg TNX-102 SL in the RELIEF trial, and we anticipate updates regarding an interim analysis for that trial in 2020.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up